USE OF CANNABINOID THERAPIES FOR ONCOLOGIC PATIENTS UNDERGOING CHEMOTHERAPY: A SYSTEMATIC REVIEW

Abstract

Introduction: Medicinal cannabis has been historically used for therapeutic purposes and, in recent decades, investigated for its antiemetic potential in cancer patients undergoing chemotherapy. Chemotherapy-induced nausea and vomiting (CINV) remain frequent and impactful adverse effects despite advances in conventional antiemetic regimens. Objective: To critically analyze the scientific evidence on the efficacy and safety of cannabinoids in managing CINV. Methodology: Narrative literature review based on qualitative analysis of 30 studies published between 2014 and 2026, including clinical trials, systematic reviews, and guidelines. Results: Cannabinoids such as dronabinol and nabilone demonstrated efficacy, particularly in refractory CINV, with additional benefits on quality of life. Discussion: Neurological adverse effects and variability in response underscore the need for cautious and individualized use. Conclusion: Cannabinoids are a promising adjuvant option in CINV management and should be used with responsible prescription based on evidence.